DelveInsight’s, “Cancer Cachexia – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Cancer Cachexia Understanding
Cancer Cachexia: Overview
Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. Cancer cachexia is a multifactorial syndrome characterized by marked loss of body weight, anorexia, asthenia, and anemia; however, in early cases these factors manifest with variable extent. It is the most common manifestation of the advanced malignant disease, leading to death. Cachexia is so destructive that it taps into other sources of energy, namely skeletal muscle and adipose tissue when the body senses a lack of nutrition. Nutritional status is compromised in direct response to tumor-induced alterations in the metabolism.
Symptoms
The most common sign of cachexia is drastic (greater than 10% of total body weight) weight loss. This includes loss of both fatty tissue and muscle mass. Other symptoms include loss of appetite, no desire to eat, lack of any sense of taste, weakness, fatigue, electrolyte imbalance, anemia (low red blood cell count), and a depressed immune system (inability to fight infection).
Diagnosis
As cachexia is sometimes difficult to recognize, doctors use a variety of criteria for diagnosis. In the most common system, the person must meet the following criteria for a cachexia diagnosis:
• non-deliberately losing more than 5 percent of their body weight over six to 12 months
• a body mass index (BMI) of less than 20 in a person under 65 years old, or a BMI of less than 22 in a person over 65 years.
• less than 10 percent body fat
Treatment
The treatment modalities at present are appetite stimulants, drugs against cachetic signaling molecules, and mediators, which help prevent and treat wasting. The current trends still under trial are anti-inflammatory antibodies and small anabolic molecules. Counteracting weight loss and anorexia is possible with central and peripheral appetite stimulants and nutritional supplements (omega 3 fatty acids and essential aminoacids). Central appetite stimulant-like megestrol acetate (synthetic progestin) acts on the hypothalamus through the oxygenic signal of neuropeptides Y (NPY). Ghrelin (peripheral agent) is a stomach neuropeptide, which increases the appetite.
Cancer Cachexia Emerging Drugs Chapters
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Cachexia Emerging Drugs
• Macimorelin: Aeterna Zentaris
Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Zentaris is conducting a pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
• PF- 06946860: Pfizer
Pfizer is conducting a phase 1, randomized, double blind, sponsor-open, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of single-dose, subcutaneous administration of PF 06946860 to healthy adult subjects. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
Further product details are provided in the report……..
Cancer Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Cancer Cachexia
There are approx. 10+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Tetra Bio-Pharma, Helsinn Healthcare etc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Amides
• Proteins and Peptides

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.
Cancer Cachexia Report Insights
• Cancer Cachexia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Cancer Cachexia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cancer Cachexia drugs?
• How many Cancer Cachexia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Cachexia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Cachexia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cancer Cachexia and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• AEterna Zentaris
• Smartfish AS
• Tetra Bio-Pharma
• Pfizer
• Helsinn Healthcare SA
• Lexicon Pharmaceuticals
Key Products
• Macimorelin
• Remune
• PPP011
• PF-06946860